Answers are grounded in this paper and cite their sources.
Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months.Trial registration number NCT03277924.
No takes yet. Share an insight, caveat, or question.
Martín‐Broto et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: